Free tool
FAERS Monitor: Orencia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125118 or its brand name (Orencia, Abatacept). Reports on generic versions are filed under their own applications.
Reports
139,985
Serious
83,534
60% of reports
Hospitalization
25,730
Death reported
9,486
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective39,195
- rheumatoid arthritis24,856
- pain22,227
- arthralgia21,734
- joint swelling20,948
- fatigue14,613
- contraindicated product administered14,115
- rash13,429
- drug intolerance13,300
- off label use12,277
- arthropathy11,847
- alopecia10,772
- synovitis10,468
- abdominal discomfort10,301
- treatment failure10,006
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 15 |
| 2005 | 12 |
| 2006 | 346 |
| 2007 | 470 |
| 2008 | 778 |
| 2009 | 313 |
| 2010 | 867 |
| 2011 | 562 |
| 2012 | 1,591 |
| 2013 | 2,580 |
| 2014 | 2,967 |
| 2015 | 4,561 |
| 2016 | 6,760 |
| 2017 | 9,924 |
| 2018 | 12,798 |
| 2019 | 14,017 |
| 2020 | 18,058 |
| 2021 | 13,719 |
| 2022 | 13,229 |
| 2023 | 9,505 |
| 2024 | 10,625 |
| 2025 | 9,654 |
| 2026 | 6,634 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,914,174 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| synovitisSignal | 10,468 | 206.3 | 200.4 | 898,915 |
| contraindicated product administeredSignal | 14,115 | 130.2 | 127.4 | 968,418 |
| rheumatoid arthritisSignal | 24,856 | 41.8 | 41.3 | 778,008 |
| arthropathySignal | 11,847 | 40.4 | 39.6 | 359,334 |
| joint swellingSignal | 20,948 | 31.3 | 30.9 | 511,408 |
| drug intoleranceSignal | 13,300 | 23.8 | 23.4 | 251,975 |
| treatment failureSignal | 10,006 | 20.5 | 20.1 | 163,836 |
| abdominal discomfortSignal | 10,301 | 9.8 | 9.6 | 76,665 |
| alopeciaSignal | 10,772 | 8.7 | 8.5 | 69,643 |
| arthralgiaSignal | 21,734 | 8.2 | 8.1 | 133,500 |
| painSignal | 22,227 | 5.6 | 5.5 | 83,447 |
| rashSignal | 13,429 | 4.7 | 4.7 | 39,270 |
| drug ineffectiveSignal | 39,195 | 4.6 | 4.5 | 113,327 |
| fatigueSignal | 14,613 | 2.9 | 2.8 | 17,944 |
| off label useSignal | 12,277 | 2.1 | 2.1 | 7,496 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.